China SXT Pharmaceuticals (SXTC) Total Non-Current Liabilities (2019 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Total Non-Current Liabilities of $697832.0 for Q1 2026, up 229.66% year-over-year from $211683.0 in Q1 2025, and up 340.93% quarter-over-quarter from $158263.0 in Q3 2025.
China SXT Pharmaceuticals (SXTC) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
China SXT Pharmaceuticals' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $697832.0 for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 229.66% year-over-year to $697832.0; the TTM figure through Mar 2026 stood at $697832.0 (up 229.66% YoY), while the FY2026 annual figure was $697832.0, up 229.66% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $697832.0, up from $158263.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $17.0 million in Q1 2022, with the low at $158263.0 in Q3 2025.
- The 5-year median for Total Non-Current Liabilities is $311512.0 (2023), against an average of $2.9 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 270065.16% in 2022, then sank 97.85% in 2023.
- China SXT Pharmaceuticals' Total Non-Current Liabilities stood at $7.2 million in 2022, then slumped by 95.66% to $311512.0 in 2023, then retreated by 4.33% to $298011.0 in 2024, then slumped by 46.89% to $158263.0 in 2025, then surged by 340.93% to $697832.0 in 2026.
- Business Quant data shows SXTC's Total Non-Current Liabilities at $697832.0 in Q1 2026, $158263.0 in Q3 2025, and $211683.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | China SXT Pharmaceuticals | 31,562.64 | -28.14 Mn | - | 697,832.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 697,832.00 |
| Sep 30, 2025 | 158,263.00 |
| Mar 31, 2025 | 211,683.00 |
| Sep 30, 2024 | 298,011.00 |
| Mar 31, 2024 | 294,667.00 |
| Sep 30, 2023 | 311,512.00 |
| Mar 31, 2023 | 365,823.00 |
| Sep 30, 2022 | 7.18 Mn |
| Mar 31, 2022 | 17.00 Mn |
| Sep 30, 2021 | 8.40 Mn |
| Mar 31, 2021 | 6,292.00 |
| Sep 30, 2020 | 15,213.00 |
| Mar 31, 2020 | 36,511.00 |
| Sep 30, 2019 | 873,282.00 |
| Mar 31, 2019 | 41,706.00 |